Tokio Marine Asset Management Co. Ltd. Has $8.73 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tokio Marine Asset Management Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 279.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,257 shares of the biopharmaceutical company's stock after acquiring an additional 9,030 shares during the quarter. Tokio Marine Asset Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $8,731,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of REGN. State Street Corp lifted its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after buying an additional 61,277 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock worth $707,759,000 after purchasing an additional 11,499 shares during the period. Swiss National Bank raised its holdings in Regeneron Pharmaceuticals by 0.6% during the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock worth $338,079,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company's stock valued at $316,957,000 after purchasing an additional 3,866 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $18.14 during trading on Wednesday, reaching $715.19. The company's stock had a trading volume of 754,919 shares, compared to its average volume of 918,809. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business's 50-day moving average price is $718.04 and its 200-day moving average price is $916.32. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The firm has a market cap of $78.59 billion, a PE ratio of 17.67, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the business posted $11.86 EPS. The business's revenue was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.